Business Wire

NV-AMBARELLA

2.1.2020 11:02:12 CET | Business Wire | Press release

Share
Ambarella Enables Artificial Intelligence on a Wide Range of Connected Cameras Using Amazon SageMaker Neo

Ambarella, Inc. (Nasdaq: AMBA), an artificial intelligence (AI) vision silicon company, today announced that Ambarella and Amazon Web Services, Inc. (AWS) customers can now use Amazon SageMaker Neo to train machine learning (ML) models once and run them on any device equipped with an Ambarella CVflow®-powered AI vision system on chip (SoC).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200102005052/en/

Until now, developers had to manually optimize ML models for devices based on Ambarella AI vision SoCs. This step could add considerable delays and errors to the application development process. Ambarella and AWS collaborated to simplify the process by integrating the Ambarella toolchain with the Amazon SageMaker Neo cloud service. Now, developers can simply bring their trained models to Amazon SageMaker Neo and automatically optimize the model for Ambarella CVflow-powered SoCs.

Customers can build an ML model using MXNet, TensorFlow, PyTorch, or XGBoost and train the model using Amazon SageMaker in the cloud or on their local machine. Then, they can upload the model to their AWS account and use Amazon SageMaker Neo to optimize the model for Ambarella SoCs. They can choose CV25, CV22, or CV2 as the compilation target. Amazon SageMaker Neo compiles the trained model into an executable that is optimized for Ambarella’s CVflow neural network accelerator. The compiler applies a series of optimizations that can make the model run up to 2x faster on the Ambarella SoC. Customers can download the compiled model and deploy it to their fleet of Ambarella-equipped devices. The optimized model runs in the Amazon SageMaker Neo runtime purpose-built for Ambarella SoCs and available for the Ambarella SDK. The Amazon SageMaker Neo runtime occupies less than 10x the disk and memory footprint of TensorFlow, MXNet, or PyTorch, making it much more efficient to deploy ML models on connected cameras.

“Ambarella is in mass production today with CVflow AI vision processors for the home monitoring, enterprise video security, and automotive markets,” said Chris Day, vice president of marketing and business development for Ambarella. “The ability to select an Ambarella SoC and compile a trained ML model with a single click is a powerful tool that makes it possible for our customers to rapidly bring the next generation of AI-enabled products to market.”

Manufactured using an advanced 10-nanometer process, Ambarella’s CVflow SoC family enables the design of compact, high-performance vision systems with ultra-low power operation. For example, the Ambarella CV22 CVflow SoC delivers computer vision processing at full 4K or 8-megapixel resolution at 30 frames per second (fps), while its image signal processor (ISP) provides outstanding imaging in low light conditions and high-contrast scenes, further enhancing the computer vision capabilities of the chip. The CV22 also includes a suite of advanced security features to protect against hacking including secure boot, TrustZone®, I/O virtualization, and support for online upgrades over the air (OTA).

“AWS has the broadest and deepest set of ML and AI services focused on solving some of the toughest challenges facing developers. Amazon SageMaker is a fully managed service that provides every developer and data scientist with the ability to build, train, and deploy machine learning models quickly,” said Bratin Saha, vice president, Machine Learning & Engines, Amazon Web Services, Inc. “We’re excited that VIVOTEK is using SageMaker Neo to simplify the deployment of ML models at the edge on Ambarella CVflow-powered IP cameras.”

VIVOTEK (TWSE:3454), a leading global IP surveillance solution provider and customer of both Ambarella and AWS, will now be able to deploy advanced ML capabilities to a new camera product line—powered by the Ambarella CV series SoCs—more quickly using Amazon SageMaker Neo. Dr. Steve Ma, vice president of engineering, Brand Business Division, VIVOTEK INC. said, “We’re excited that we will be able to explore training and deploying the machine learning models increasingly demanded by our customers to our future Ambarella CV series powered cameras with Amazon SageMaker Neo, potentially saving us months of hand-tuning the individual models for optimal performance on the edge. Using Amazon SageMaker Neo ensures that our IP camera solutions are fully able to leverage the market-leading computer vision capabilities of the Ambarella SoC.”

Ambarella will demonstrate the integration with Amazon SageMaker Neo during CES 2020 to select customers and partners.

The URL for this news release and the related image: https://www.ambarella.com/news-events/

About Ambarella

Ambarella’s products are used in a wide variety of human and computer vision applications, including video security, advanced driver assistance systems (ADAS), electronic mirror, drive recorder, driver/cabin monitoring, autonomous driving, and robotic applications. Ambarella’s low-power system on chips (SoCs) offer high-resolution video compression, advanced image processing, and powerful deep neural network processing to enable intelligent cameras to extract valuable data from high-resolution video streams. For more information, please visit www.ambarella.com

All brand names, product names, or trademarks belong to their respective holders. Ambarella reserves the right to alter product and service offerings, specifications and pricing at any time without notice. ©2020 Ambarella. All rights reserved.

Link:

ClickThru

Social Media:

https://www.facebook.com/ambarellacorp/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye